2005
DOI: 10.1111/j.0303-6987.2005.00495.x
|View full text |Cite
|
Sign up to set email alerts
|

WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects

Abstract: Abstract:The new WHO/EORTC classification for cutaneous lymphomas comprises mature T-cell and natural killer (NK)-cell neoplasms, mature B-cell neoplasms, and immature hematopoietic malignancies. It reflects the unique features of lymphoproliferative diseases of the skin, and at the same time it is as compatible as possible with the concepts underlying the WHO classification for nodal lymphomas and the EORTC classification of cutaneous lymphomas. This article reviews the histological, phenotypical, and molecul… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

6
255
3
19

Year Published

2007
2007
2016
2016

Publication Types

Select...
5
3

Relationship

2
6

Authors

Journals

citations
Cited by 306 publications
(283 citation statements)
references
References 204 publications
(202 reference statements)
6
255
3
19
Order By: Relevance
“…[1][2][3] Adults and the elderly are most commonly affected, with a median age at presentation in the mid-50s and a male-to-female ratio of approximately 2:1. The disease slowly progresses for years, evolving from erythematous patches on sun-protected skin to plaques to tumors.…”
Section: Commentmentioning
confidence: 99%
See 2 more Smart Citations
“…[1][2][3] Adults and the elderly are most commonly affected, with a median age at presentation in the mid-50s and a male-to-female ratio of approximately 2:1. The disease slowly progresses for years, evolving from erythematous patches on sun-protected skin to plaques to tumors.…”
Section: Commentmentioning
confidence: 99%
“…Early MF (patch phase) is clinically characterized by large, welldemarcated lesions (typically, .1 lesion .5 cm in diameter) that vary in size and shape over time (progression and regression) but that tend to enlarge and become more numerous with continued disease (Figure 2, A). [2][3][4][5] The clinical course generally remains indolent, with 5-year, disease-specific survival approaching 90%. 1 However, prognosis and therapeutic options depend on the type of lesion (patch, plaque, or tumor), the extent of cutaneous involvement, and the presence of extracutaneous disease and largecell transformation.…”
Section: Commentmentioning
confidence: 99%
See 1 more Smart Citation
“…[3][4][5] It is listed as a provisional entity in the World Health Organization (WHO)-European Organization for Research and Treatment of Cancer (EORTC) classification and represents a distinct lymphoma entity in the WHO classification (fourth edition, 2008). 4,6 Histologically, CGD-TCL presents with epidermotropic, dermal and/or subcutaneous infiltrates, or combinations of these patterns even in the same individual.…”
Section: Introductionmentioning
confidence: 99%
“…A primeira diz que há uma pequena população de linfócitos T circulantes que apresentam a expressão de CD20 como fenótipo normal, cuja função ainda não foi elucidada (QUINTANILLA-MARTINEZ et al, 1994;RAHEMTULLAH et al, 2008;BALMER et al, 2009;MARTIN et al, 2011). A outra teoria fala que o CD20 pode ser considerado um marcador de ativação dos linfócitos, isso porque a administração in vitro de interleucina-2 em células de linfonodos de macaco induziu a expressão de CD20 pelos linfócitos T (TAKAMI et al, 1998;RAHEMTULLAH et al, 2008;BALMER et al, 2009;MARTIN et al, 2011 (BURG et al, 2005;WILLEMZE et al, 2005;KO, 2006).…”
Section: Dedicatóriaunclassified